Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dCD133KDEL in Advanced Solid Tumors
NCT02845414Phase 1Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Dec 2018
- Primary completion
- Jan 2022
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dCD133KDEL in solid tumor, sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at Day 28. Planned start Dec 2018; status: withdrawn.
02
Drugs
dCD133KDEL
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02845414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02845414.